Recent Advances in Endometrial Cancer

Tran, Arthur Quan; Gehrig, Paola A.

doi:10.12688/f1000research.10020.1

Cited by 52 publications

(42 citation statements)

References 89 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular characterization has also been used in clinical trials to investigate potential therapeutic targets in EC, focusing on frequently mutated pathways such as PI3K/PTEN/AKT/mTOR. However, at present, further studies are needed to define molecular biomarkers that more accurately reflect tumor susceptibility to targeted‐therapies …”

Section: Molecular Tests In Endometrial Liquid‐based Cytologymentioning

confidence: 99%

The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology

Fulciniti

Yanoh²,

Karakitsos

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

Section: Molecular Tests In Endometrial Liquid‐based Cytologymentioning

confidence: 99%

The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology

Fulciniti

Yanoh²,

Karakitsos

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1). War has many negative effects on human health.…”

Section: War and Women's Healthmentioning

confidence: 99%

The Comparative Effect of Combination of Metformin and Megestrol Acetate With Megestrol Acetate Alone on Endometrial Growth Disorders

Sayyah-Melli¹,

Pourazad²,

Gharebaghi³

et al. 2017

International Journal of Women’s Health and Reproduction Scienc

View full text Add to dashboard Cite

“…The current treatment strategies also reflect such similarities: both serous-like EC and serous OvCa are commonly treated with platinum-or taxane-based chemotherapies, although the responsiveness varies (Moxley & McMeekin, 2010;Brasseur, Gévry & Asselin, 2017;Cortez et al, 2018). In comparison, type I endometroid cancer is more frequently treated with adjuvant radiotherapy (Hopkins Hospital Edward Tanner et al, 2017). Also, there is not a single targeted therapy that works well for serous-like EC and serous OvCa, but type I endometroid EC patients might be treated with immunotherapy (Piulats & Matias-Guiu, 2016).…”

Section: Introductionmentioning

confidence: 99%

Peer Review #2 of "A multiomics comparison between endometrial cancer and serous ovarian cancer (v0.1)"

2020

View full text Add to dashboard Cite

Background. Endometrial carcinoma (EC) and serous ovarian carcinoma (OvCa) are both among the common cancer types in women. EC can be divided into two subtypes, endometroid EC and serous-like EC, with distinct histological characterizations and molecular phenotypes. There is an increasing awareness that serous-like EC resembles serous OvCa in genetic landscape, but a clear relationship between them is still lacking. Methods. Here, we took advantage of the large-scale molecular profiling of The Cancer Genome Atlas(TCGA) to compare the two EC subtypes and serous OvCa. We used bioinformatics data analytic methods to systematically examine the somatic mutation (SM) and copy number alteration (SCNA), gene expression, pathway activities, survival gene signatures and immune infiltration. Based on these quantifiable molecular characterizations, we asked whether serous-like EC should be grouped more closely to serous OvCa, based on the context of being serous-like; or it should be grouped more closely to endometroid EC, based on the same organ origin. Results. We found that although serous-like EC and serous OvCa share some common genotypes, including mutation and copy number alteration, they differ in molecular phenotypes such as gene expression and signaling pathway activity. Moreover, no shared prognostic gene signature was found, indicating that they use unique genes governing tumor progression. Finally, although the endometrioid EC and serous OvCa are both highly immune infiltrated, the immune cell composition in serous OvCa is mostly immune suppressive, whereas endometrioid EC has a higher level of cytotoxic immune cells. Overall, our genetic aberration and molecular phenotype characterizations indicated that serous-like EC and serous OvCa cannot be simply treated as a simple "serous" cancer type. In particular, additional attention should be paid to their unique gene activities and tumor microenvironments for novel targeted therapy development.

show abstract

Recent Advances in Endometrial Cancer

Cited by 52 publications

References 89 publications

The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology

The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology

The Comparative Effect of Combination of Metformin and Megestrol Acetate With Megestrol Acetate Alone on Endometrial Growth Disorders

Peer Review #2 of "A multiomics comparison between endometrial cancer and serous ovarian cancer (v0.1)"

Contact Info

Product

Resources

About